Eli Lilly Reports Strong Earnings and Raises Outlook Amid Surge in Weight-Loss Drug Demand
Eli Lilly (LLY) reported strong first-quarter earnings and raised its full-year sales outlook, driven by increased demand for its weight-loss drugs Mounjaro and Zepbound. The company also received FDA approval for its new weight-loss pill, Foundayo, which could further boost its market position. Shares of Eli Lilly rose over 9% following the results.
Topics: Earnings FDA Approval Market Recovery Stock Performance Weight-Loss Drugs